Following Strong Growth, Hims & Hers Appoints Chief Growth Officer

On the heels of strong Q2 earnings, Hims & Hers Health, Inc., has appointed Mike Chi as the company’s first-ever chief growth officer. Chi brings years of experience in the women’s market and will be responsible in this new role for driving continued growth across Hims & Hers’ multi-specialty telehealth platform.

“Mike has a proven record of delivering strong results, specifically when it comes to driving growth in traditionally women’s focused markets,” said Hims & Hers CEO Andrew Dudum. “Mike will help lead the charge as we look to continue delivering robust growth in our established Hims categories and double down on our emerging new Hers-focused specialties, such as mental health and dermatology. He is truly a unique mind with a relentless work ethic and expertise in channel-level marketing that is rarely seen in marketing leaders.”

Chi joined Hims & Hers earlier this year, bringing a wealth of experience across marketing, strategy, positioning, and product, with specific expertise in the women’s market. Previously he was the chief marketing officer at Zola and held senior positions at INTERMIX and Gilt Groupe. He holds an MBA from Columbia University.

In his role as chief growth officer, Chi will be responsible for driving continued growth across Hims & Hers, which has posted strong results recently. In 2020, revenue grew by 80%. In the first and second quarters of 2021, revenue grew year-over-year by 74% and 69% respectively, in each case exceeding guidance and causing the company to raise full-year expectations. Among the company’s fastest growing categories are women’s hair and skin care and mental health services, all of which Chi is well positioned to help continue growing.

Hims & Hers recently acquired Apostrophe, a teledermatology specialist and compounding pharmacy, expanding its investment in the growing dermatology vertical; and Honest Health, a London-based vertical health platform, laying the foundation for future expansion in the UK and Europe.

Read the original press release here.